{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:29:32Z","timestamp":1793478572608,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite the availability of conjugate pneumococcal vaccines, children with high-risk conditions remain vulnerable to invasive pneumococcal disease (IPD). This study sought to describe IPD prevalence, vaccination and outcomes among high-risk children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We used International Classification of Disease10 discharge and microbiology codes to identify patients hospitalized for IPD at a large pediatric hospital from January 1, 2009, to December 31, 2018. Patients were considered high-risk if they had: primary immunodeficiency, asplenia, transplant, active malignancy, sickle cell disease, cochlear implant, nephrotic syndrome, chronic lung disease, cerebrospinal fluid leak, HIV or used immunosuppressive therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total 94 high-risk patients were hospitalized for IPD. The most common high-risk conditions included malignancy (n = 33, 35%), solid-organ or bone marrow transplant (n = 17, 18%) and sickle cell disease (n = 14, 15%). Bacteremia was the most common presentation (n = 81, 86%) followed by pneumonia (n = 23, 25%) and meningitis (n = 9, 10%). No deaths occurred. Of 66 patients with known pneumococcal vaccination status, 15 (23%) were unvaccinated, and 51 (77%) received at least one dose of a pneumococcal vaccine; 20 received all four recommended pneumococcal conjugate vaccine (PCV) doses. Only three children received PPSV23. Of 20 children with no or partial (&lt;3 doses) immunization, 70% (14) of IPD episodes were due to vaccine-preventable serotypes. Of 66 known IPD serotypes, 17% (n = 11) were covered by PCV13, 39% (n = 26) were covered by PPSV23 and 39% (n = 26) were nonvaccine serotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Despite the availability of effective pneumococcal vaccines, IPD persists among children with high-risk conditions. Improving PCV13 and PPSV23 vaccination could significantly reduce IPD; most episodes were due to vaccine-preventable serotypes in incompletely immunized patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000003748","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T16:00:56Z","timestamp":1669824056000},"page":"74-81","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Invasive Pneumococcal Disease in High-risk Children: A 10-Year Retrospective Study"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-5625","authenticated-orcid":false,"given":"Jacqui","family":"van Warmerdam","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Campigotto","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Division of Microbiology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Bitnun","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Division of Infectious Disease, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"MacDougall","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Kirby-Allen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Department of Otolaryngology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Papsin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Department of Otolaryngology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"McGeer","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Division of Infectious Disease, Mount Sinai Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upton","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Division of Infectious Disease, The Hospital for Sick Children, Toronto, ON, Canada"},{"name":"Child Health Evaluative Sciences, Hospital for Sick Children Research Institute, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9809-0822","authenticated-orcid":false,"given":"Shaun K.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"Division of Infectious Disease, The Hospital for Sick Children, Toronto, ON, Canada"},{"name":"Child Health Evaluative Sciences, Hospital for Sick Children Research Institute, Toronto, ON, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"R1-20260716","first-page":"93104","article-title":"Pneumococcal conjugate vaccine for childhood immunization--WHO position paper.","volume":"82","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"key":"R3-20260716","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1542\/peds.2007-1510","article-title":"Risks of invasive pneumococcal disease in children with underlying chronic diseases.","volume":"122","author":"Hjuler","year":"2008","journal-title":"Pediatrics"},{"key":"R4-20260716","first-page":"1","article-title":"Modlin J, et al. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"R5-20260716","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00006454-200204000-00004","article-title":"Invasive pneumococcal infections in children with asplenia.","volume":"21","author":"Schutze","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20260716","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1017\/S0950268810000919","article-title":"Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies.","volume":"138","author":"Wong","year":"2010","journal-title":"Epidemiol Infect"},{"key":"R7-20260716","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.285.13.1729","article-title":"Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era.","volume":"285","author":"Robinson","year":"2001","journal-title":"JAMA"},{"key":"R8-20260716","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1086\/377736","article-title":"Recurrent invasive pneumococcal disease: a population-based assessment.","volume":"37","author":"King","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R9-20260716","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1473-3099(05)70083-9","article-title":"Epidemiological differences among pneumococcal serotypes.","volume":"5","author":"Hausdorff","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"R11-20260716","first-page":"521","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6\u201318 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Bennett","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"ACS-12","key":"R12-20260716","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14745\/ccdr.v36i00a12","article-title":"Update on the use of conjugate pneumococcal vaccines in childhood: an Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)(\u2020). (1188-4169 (Print)).","volume":"36","author":"Desai","year":"2010","journal-title":"Can Commun Dis Rep"},{"key":"R13-20260716","first-page":"699","article-title":"The quellung reaction, a neglected microbiologic technique.","volume":"43","author":"Austrian","year":"1976","journal-title":"Mt Sinai J Med"},{"key":"R14-20260716","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/JCM.42.6.2518-2522.2004","article-title":"Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex).","volume":"42","author":"Slotved","year":"2004","journal-title":"J Clin Microbiol"},{"key":"R15-20260716","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/cid\/civ803","article-title":"Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs.","volume":"62","author":"Shigayeva","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R16-20260716","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/1932296820978399","article-title":"How to best protect people with diabetes from the impact of SARS-CoV-2: report of the international COVID-19 and diabetes summit.","volume":"15","author":"Zhang","year":"2021","journal-title":"J Diabetes Sci Technol"},{"key":"R17-20260716","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(16)00052-7","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.","volume":"4","author":"Moore","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R22-20260716","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/ijcp.12234","article-title":"The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe.","volume":"68","author":"Rose","year":"2014","journal-title":"Int J Clin Pract"},{"key":"R23-20260716","doi-asserted-by":"crossref","first-page":"e1000081","DOI":"10.1371\/journal.pmed.1000081","article-title":"Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study.","volume":"6","author":"Harboe","year":"2009","journal-title":"PLoS Med"},{"key":"R24-20260716","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1093\/cid\/ciaa163","article-title":"Waning vaccine immunity and vaccination \/responses in children treated for acute lymphoblastic leukemia: a Canadian immunization research network study.","volume":"71","author":"Top","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R25-20260716","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1600-6143.2006.01705.x","article-title":"Invasive pneumococcal disease in solid organ transplant recipients\u201410-year prospective population surveillance.","volume":"7","author":"Kumar","year":"2007","journal-title":"Am J Transplant"},{"key":"R26-20260716","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1399-3046.2005.00275.x","article-title":"Invasive pneumococcal disease in pediatric organ transplant recipients: a high-risk population.","volume":"9","author":"Tran","year":"2005","journal-title":"Pediatr Transplant"},{"key":"R27-20260716","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. (1474-4457 (Electronic)).","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R29-20260716","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/vaccines8010132","article-title":"Development of next generation streptococcus pneumoniae vaccines conferring broad protection.","volume":"8","author":"Masomian","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"R30-20260716","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1139\/cjm-2013-0614","article-title":"Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010\u20132012.","volume":"59","author":"Demczuk","year":"2013","journal-title":"Canadian J Microbiol"},{"key":"R31-20260716","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3201\/eid1907.121830","article-title":"Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). (1080-6059 (Electronic)).","volume":"19","author":"Richter","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"R32-20260716","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1469-0691.2010.03182.x","article-title":"Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. (1469-0691 (Electronic)).","volume":"16","author":"Li\u00f1ares","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"R33-20260716","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/INF.0b013e31805cdbeb","article-title":"Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. (0891-3668 (Print)).","volume":"26","author":"Messina","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R34-20260716","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/cid\/ciu497","article-title":"Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance.","volume":"59","author":"Kuster","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R35-20260716","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/jac\/dkh118","article-title":"Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP).","volume":"53","author":"Song","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R36-20260716","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1128\/JCM.41.9.4194-4216.2003","article-title":"Clonal distribution of invasive pneumococcal isolatesfrom children and selected adults in the United States prior to7-valent conjugate vaccine introduction.","volume":"41","author":"Gertz","year":"2003","journal-title":"J Clin Microbiol"},{"key":"R37-20260716","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jac\/dkp210","article-title":"Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain.","volume":"64","author":"Ardanuy","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R38-20260716","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1086\/528996","article-title":"Population snapshot of emergent streptococcus pneumoniae serotype 19A in the United States, 2005.","volume":"197","author":"Moore","year":"2008","journal-title":"J Infect Dis"},{"key":"R39-20260716","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJM200012283432603","article-title":"Increasing prevalence of multidrug-resistant streptococcus pneumoniae in the United States.","volume":"343","author":"Whitney","year":"2000","journal-title":"N Engl J Med"},{"key":"R40-20260716","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/INF.0b013e3181fab1cf","article-title":"Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine era.","volume":"30","author":"Hsu","year":"2011","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:02:20Z","timestamp":1784224940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003748","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,18]]}}}